|Mr. David T. Domzalski||CEO & Director||891k||N/A||1967|
|Mr. Ilan Hadar M.B.A., MBA||CFO & Country Mang.||794.74k||N/A||1969|
|Ms. Mutya Harsch||Gen. Counsel & Chief Legal Officer||556k||N/A||1975|
|Dr. Darrell S. Rigel M.D., MS||Consultant||40.2k||N/A||1950|
|Dr. Iain A. Stuart||Chief R&D Officer||N/A||N/A||1973|
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.
Foamix Pharmaceuticals Ltd.’s ISS Governance QualityScore as of April 1, 2019 is 2. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 1; Compensation: 6.